Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

Cellular senescence is a key mechanism that drives age-related diseases, but has yet to be targeted therapeutically in humans. Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal cellular senescence-associated disease. Selectively ablating senescent cells using dasatinib plus quercetin (DQ) alleviates IPF-related dysfunction in bleomycin-administered mice.A two-center, open-label study of intermittent DQ (D:100 mg/day, Q:1250 mg/day,...